ELSEVIER

Clinica Chimica Acta 260 (1997) 217–218

Author index

Volume 260 (1997)

Alberti, M.M., see Dyer, R.G. **260**, 1
Author, D., The effect of analytic uncertainty on clinical decision making **260**, 97

Barragán-González, E., J.A. López-Guerrero, P. Bolufer-Gilabert, M. Sanz-Alonso, J. De la Rubia-Comos, A. Sempere-Talens, The type of reverse transcriptase affects the sensitivity of some reverse transcription PCR methods **260**, 73
Bertuzzi, A., see Mingrone, G. **260**, 27
Biondi, R., see Capodicasa, E. **260**, 35
Blaabjerg, O., see Hyltoft Petersen, P. **260**, 189
Bolufer-Gilabert, P., see Barragán-González, E. **260**, 73
Büttner, J., Diagnostic validity as a theoretical concept and as a measurable quantity **260**, 131

Capodicasa, E., C. Tassi, R. Rossi, L. Mezzasoma, M. Valiani, R. Biondi, Effect of antiorthostatic hypokinetic/hypodynamia on urinary endothelin-1 and *N*-acetyl-β-D-glucosaminidase excretion in rats **260**, 35
Chiang, A.N., B. Hwang, G.C. Shaw, B.C. Lee, J.H. Lu, C.C.L. Meng, P. Chou, Changes in plasma levels of lipids and lipoprotein composition in patients with Kawasaki disease **260**, 15
Chou, P., see Chiang, A.N. **260**, 15

Davie, S.J., see Gould, B.J. **260**, 49
De la Rubia-Comos, J., see Barragán-González, E. **260**, 73
De Smet, R., see Mingrone, G. **260**, 27
de Verdier, C.-H., see Hyltoft Petersen, P. **260**, 189
Doumas, B.T., The evolution and limitations of accuracy and precision standards **260**, 145
Dyer, R.G., M.W. Stewart, J. Mitcheson, K. George, M.M. Alberti, M.F. Laker, 7-Ketocholesterol, a specific indicator of lipoprotein oxidation, and malondialdehyde in non-insulin dependent diabetes and peripheral vascular disease **260**, 1

Fraser, C.G., see Hyltoft Petersen, P. **260**, 189

Gandolfi, A., see Mingrone, G. **260**, 27
George, K., see Dyer, R.G. **260**, 1
Gould, B.J., S.J. Davie, J.S. Yudkin, Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia **260**, 49
Greco, A.V., see Mingrone, G. **260**, 27
Groth, T., see Hyltoft Petersen, P. **260**, 189

Handorf, C.R., Assuring quality in laboratory testing at the point of care **260**, 207
Howanitz, P.J., G.A. Tetrault, S.J. Steindel, Clinical laboratory quality control: a costly process now out of control **260**, 163
Hørder, M., see Hyltoft Petersen, P. **260**, 189
Hwang, B., see Chiang, A.N. **260**, 15
Hyltoft Petersen, P., C.-H. de Verdier, T. Groth, C.G. Fraser, O. Blaabjerg, M. Hørder, The influence of analytical bias on diagnostic misclassifications **260**, 189

Klee, G., A conceptual model for establishing tolerance limits for analytic bias and imprecision based on variations in population test distributions **260**, 175

0009-8981/97/$17.00 © 1997 Elsevier Science B.V. All rights reserved

Laker, M.F., see Dyer, R.G. **260**, 1
Lascelles, C.V., P.A. Quant, Investigation of human hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme A synthase in post-mortem or biopsy tissue **260**, 85
Lee, B.C., see Chiang, A.N. **260**, 15
López-Guerrero, J.A., see Barragán-González, E. **260**, 73
Lu, J.H., see Chiang, A.N. **260**, 15

Meng, C.C.L., see Chiang, A.N. **260**, 15
Mezzasoma, L., see Capodicasa, E. **260**, 35
Mingrone, G., R. De Smet, A.V. Greco, A. Bertuzzi, A. Gandolfi, S. Ringoir, R. Vanholder, Serum uremic toxins from patients with chronic renal failure displace the binding of L-tryptophan to human serum albumin **260**, 27
Mitcheson, J., see Dyer, R.G. **260**, 1

Quant, P.A., see Lascelles, C.V. **260**, 85

Ringoir, S., see Mingrone, G. **260**, 27
Rojas, G., see Sorell Gómez, L. **260**, 65
Rossi, R., see Capodicasa, E. **260**, 35

Sanz-Alonso, M., see Barragán-González, E. **260**, 73
Sempere-Talens, A., see Barragán-González, E. **260**, 73
Shaw, G.C., see Chiang, A.N. **260**, 15
Sorell Gómez, L., G. Rojas, A simple visual immunoassay (VIA) for rapid identification of high lipoprotein(a) blood levels **260**, 65
Steindel, S.J., see Howanitz, P.J. **260**, 163
Stewart, M.W., see Dyer, R.G. **260**, 1

Tassi, C., see Capodicasa, E. **260**, 35
Tetrault, G.A., see Howanitz, P.J. **260**, 163

Valiani, M., see Capodicasa, E. **260**, 35
Vanholder, R., see Mingrone, G. **260**, 27

Werner, M., Linking analytic performance goals to medical outcome **260**, 99
Witte, D.L., The complex connections between test properties and relevant outcomes: widening the perspective **260**, 117

Yudkin, J.S., see Gould, B.J. **260**, 49

ELSEVIER

Clinica Chimica Acta 260 (1997) 219–221

Subject index

Volume 260 (1997)

Albumin binding; Uremic toxins; Chronic renal failure; L-Tryptophan **260**, 27

Aminoglycosides; Predictive value; Cognition; Hemochromatosis; Error rates; Analytical goals **260**, 117

Analytical goals; Analytical quality specifications; Glycated haemoglobin; S-Cholesterol; S-Transferrin **260**, 189

Analytical goals; Predictive value; Cognition; Hemochromatosis; Aminoglycosides; Error rates **260**, 117

Analytical quality specifications; Analytical goals; Glycated haemoglobin; S-Cholesterol; S-Transferrin **260**, 189

Analytic bias; Analytic goals; Imprecisions; Clinical decision theory; Quality control; Tolerance limits **260**, 175

Analytic goals; Analytic bias; Imprecisions; Clinical decision theory; Quality control; Tolerance limits **260**, 175

Analytic performance; Medical goals; Tolerance limits; Clinical decisions; Medical reasoning **260**, 99

Antiorthostasis; Endothelin-1 (ET-1); *N*-acetyl-β-D-glucosaminidase (NAG); Kidney; Urine; Rat **260**, 35

Apolipoproteins; Lipids; Lipoproteins; Kawasaki disease **260**, 15

Atherosclerosis; Diabetes; Malondialdehyde; Lipoproteins; 7-Ketocholesterol **260**, 1

Avian Myelomatosis Virus (AMV); Reverse transcription (RT); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RARα; CBFβ/MYH11; Cytokeratin K19 **260**, 73

CBFβ/MYH11; Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RARα; Cytokeratin K19 **260**, 73

Chronic renal failure; Uremic toxins; L-Tryptophan; Albumin binding **260**, 27

Clinical assay; Human hepatic mHMG-CoA synthase; Succinylation; Ketogenesis; Liver needle biopsy; Postmortem tissue **260**, 85

Clinical decisions; Analytic performance; Medical goals; Tolerance limits; Medical reasoning **260**, 99

Clinical decision theory; Analytic goals; Analytic bias; Imprecisions; Quality control; Tolerance limits **260**, 175

Cognition; Predictive value; Hemochromatosis; Aminoglycosides; Error rates; Analytical goals **260**, 117

Cytokeratin K19; Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RARα; CBFβ/MYH11 **260**, 73

0009-8981/97/$17.00 © 1997 Elsevier Science B.V. All rights reserved

Diabetes; Atherosclerosis; Malondialdehyde; Lipoproteins; 7-Ketocholesterol **260**, 1

Diagnostic validity; Laboratory test; Laboratory finding; Efficiency **260**, 131

2,3-Diphosphoglycerate; Glycated haemoglobin; Glycated albumin; Fructosamine; Glucose tolerance test; Glucose permeability of erythrocytes **260**, 49

Efficiency; Laboratory test; Laboratory finding; Diagnostic validity **260**, 131

Endothelin-1 (ET-1); Antiorthostasis; *N*-acetyl-β-D-glucosaminidase (NAG); Kidney; Urine; Rat **260**, 35

Error rates; Predictive value; Cognition; Hemochromatosis; Aminoglycosides; Analytical goals **260**, 117

Fructosamine; Glycated haemoglobin; Glycated albumin; Glucose tolerance test; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260**, 49

Glucose permeability of erythrocytes; Glycated haemoglobin; Glycated albumin; Fructosamine; Glucose tolerance test; 2,3-Diphosphoglycerate **260**, 49

Glucose tolerance test; Glycated haemoglobin; Glycated albumin; Fructosamine; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260**, 49

Glycated albumin; Glycated haemoglobin; Fructosamine; Glucose tolerance test; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260**, 49

Glycated haemoglobin; Analytical goals; Analytical quality specifications; S-Cholesterol; S-Transferrin **260**, 189

Glycated haemoglobin; Glycated albumin; Fructosamine; Glucose tolerance test; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260**, 49

Hemochromatosis; Predictive value; Cognition; Aminoglycosides; Error rates; Analytical goals **260**, 117

Human hepatic mHMG-CoA synthase; Succinylation; Ketogenesis; Clinical assay; Liver needle biopsy; Postmortem tissue **260**, 85

Imprecisions; Analytic goals; Analytic bias; Clinical decision theory; Quality control; Tolerance limits **260**, 175

Kawasaki disease; Lipids; Lipoproteins; Apolipoproteins **260**, 15

7-Ketocholesterol; Atherosclerosis; Diabetes; Malondialdehyde; Lipoproteins **260**, 1

Ketogenesis; Human hepatic mHMG-CoA synthase; Succinylation; Clinical assay; Liver needle biopsy; Postmortem tissue **260**, 85

Kidney; Antiorthostasis; Endothelin-1 (ET-1); *N*-acetyl-β-D-glucosaminidase (NAG); Urine; Rat **260**, 35

Laboratory costs; Quality control; Timeliness; Quality costs; Quality improvement; Laboratory management **260**, 163

Laboratory finding; Laboratory test; Diagnostic validity; Efficiency **260**, 131

Laboratory management; Quality control; Laboratory costs; Timeliness; Quality costs; Quality improvement **260**, 163

Laboratory testing; Point of care; Quality **260**, 207

Laboratory test; Laboratory finding; Diagnostic validity; Efficiency **260**, 131

Lipids; Lipoproteins; Apolipoproteins; Kawasaki disease **260**, 15

Lipoprotein(a); Visual immunoassay; Monoclonal antibodies **260**, 65

Lipoproteins; Atherosclerosis; Diabetes; Malondialdehyde; 7-Ketocholesterol **260**, 1

Lipoproteins; Lipids; Apolipoproteins; Kawasaki disease **260**, 15

Liver needle biopsy; Human hepatic mHMG-CoA synthase; Succinylation; Ketogenesis; Clinical assay; Postmortem tissue **260**, 85

L-Tryptophan; Uremic toxins; Chronic renal failure; Albumin binding **260**, 27

Malondialdehyde; Atherosclerosis; Diabetes; Lipoproteins; 7-Ketocholesterol **260**, 1

Medical goals; Analytic performance; Tolerance limits; Clinical decisions; Medical reasoning **260**, 99

Medical reasoning; Analytic performance; Medical goals; Tolerance limits; Clinical decisions **260**, 99

Monoclonal antibodies; Lipoprotein(a); Visual immunoassay **260**, 65

Murine Moloney Leukaemia Virus (MMLV); Reverse transcription (RT); Avian Myelomatosis Virus (AMV); RT-PCR; PML/RARα; CBFβ/MYH11; Cytokeratin K19 **260**, 73

***N*-acetyl-β-D-glucosaminidase (NAG)**; Antiorthostasis; Endothelin-1 (ET-1); Kidney; Urine; Rat **260**, 35

PML/RARα; Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; CBFβ/MYH11; Cytokeratin K19 **260**, 73

Point of care; Laboratory testing; Quality **260**, 207

Postmortem tissue; Human hepatic mHMG-CoA synthase; Succinylation; Ketogenesis; Clinical assay; Liver needle biopsy **260**, 85

Predictive value; Cognition; Hemochromatosis; Aminoglycosides; Error rates; Analytical goals **260**, 117

Quality control; Analytic goals; Analytic bias; Imprecisions; Clinical decision theory; Tolerance limits **260**, 175

Quality control; Laboratory costs; Timeliness; Quality costs; Quality improvement; Laboratory management **260**, 163

Quality costs; Quality control; Laboratory costs; Timeliness; Quality improvement; Laboratory management **260**, 163

Quality improvement; Quality control; Laboratory costs; Timeliness; Quality costs; Laboratory management **260**, 163

Quality; Laboratory testing; Point of care **260**, 207

Rat; Antiorthostasis; Endothelin-1 (ET-1); *N*-acetyl-β-D-glucosaminidase (NAG); Kidney; Urine **260**, 35

Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RARα; CBFβ/MYH11; Cytokeratin K19 **260**, 73

RT-PCR; Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); PML/RARα; CBFβ/MYH11; Cytokeratin K19 **260**, 73

S-Cholesterol; Analytical goals; Analytical quality specifications; Glycated haemoglobin; S-Transferrin **260**, 189

S-Transferrin; Analytical goals; Analytical quality specifications; Glycated haemoglobin; S-Cholesterol **260**, 189

Succinylation; Human hepatic mHMG-CoA synthase; Ketogenesis; Clinical assay; Liver needle biopsy; Postmortem tissue **260**, 85

Timeliness; Quality control; Laboratory costs; Quality costs; Quality improvement; Laboratory management **260**, 163

Tolerance limits; Analytic goals; Analytic bias; Imprecisions; Clinical decision theory; Quality control **260**, 175

Tolerance limits; Analytic performance; Medical goals; Clinical decisions; Medical reasoning **260**, 99

Uremic toxins; Chronic renal failure; L-Tryptophan; Albumin binding **260**, 27

Urine; Antiorthostasis; Endothelin-1 (ET-1); *N*-acetyl-β-D-glucosaminidase (NAG); Kidney; Rat **260**, 35

Visual immunoassay; Lipoprotein(a); Monoclonal antibodies **260**, 65